A randomised, double-blind, two-period study to evaluate the safety and efficacy of etanercept on skin and joint disease in psoriasis subjects with psoriatic arthritis.

Trial Profile

A randomised, double-blind, two-period study to evaluate the safety and efficacy of etanercept on skin and joint disease in psoriasis subjects with psoriatic arthritis.

Completed
Phase of Trial: Phase IV

Latest Information Update: 03 Aug 2017

At a glance

  • Drugs Etanercept (Primary)
  • Indications Psoriasis; Psoriatic arthritis
  • Focus Therapeutic Use
  • Acronyms PRESTA
  • Sponsors Wyeth
  • Most Recent Events

    • 03 Aug 2017 Results of pooled analysis of 10 trials (NCT00245960, NCT00111449, NCT00663052, NCT00454584) generating evidence concerning the number of patients dropping out of etanercept trials published in the British Journal of Dermatology
    • 17 Jun 2017 Results of post hoc analysis presented at the 18th Annual Congress of the European League Against Rheumatism
    • 13 Jun 2015 Results of post-hoc analysis presented at the 16th Annual Congress of the European League Against Rheumatism.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top